MedAvante Surpasses 630,000 Electronic Source (eSource) Clinical Trial Assessments

Extends Leadership Position in Electronic Clinical Outcome Assessments (eCOA)

Hamilton, NJ (November 15, 2016) — MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, announced significant advances in the deployment of the groundbreaking Virgil® Investigative Study Platform for global clinical trials as the source (eSource) data platform begins its third year in worldwide use.

Two Former Covance Senior Executives Join MedAvante Board of Directors

Hamilton, NJ (June 21, 2016) – MedAvante, Inc., the leader in technology-based clinical trial services for central nervous system (CNS) diseases, announced two new members of its Board of Directors: Richard F. Cimino, former Covance, Inc. EVP and Group President of Clinical Development and Commercialization Services, and Nigel Brown, former Corporate Vice President of Business Development and Strategy at Covance.

MedAvante Research Shows Improved Psychiatric Assessments in Clinical Trials 

Virgil eCOA Reduces HAM-D Item Scoring Errors Up To 70%

Scottsdale AZ (June 1, 2016) – MedAvante, Inc., the leading global scientific clinical data services company, today presented research at the 2016 American Society of Clinical Psychopharmacology (ASCP) meeting quantifying error reduction in actual clinical trials of treatments for major depressive disorder (MDD). The new study compares traditional paper-based assessments in clinical trials with the Virgil® Investigative Study Platform, which uses a digital tablet to administer and score clinical outcome assessments (eCOA) and capture source data (eSource).